Literature DB >> 17266737

Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.

Mark J Millan1, Benjamin Di Cara, Anne Dekeyne, Fany Panayi, Lotte De Groote, Dorothée Sicard, Laetitia Cistarelli, Rodolphe Billiras, Alain Gobert.   

Abstract

Though dopaminergic mechanisms modulate cholinergic transmission and cognitive function, the significance of specific receptor subtypes remains uncertain. Here, we examined the roles of dopamine D(3) versus D(2) receptors. By analogy with tacrine (0.16-2.5 mg/kg, s.c.), the selective D(3) receptor antagonists, S33084 (0.01-0.63) and SB277,011 (0.63-40.0), elicited dose-dependent, pronounced and sustained elevations in dialysis levels of acetylcholine (ACh) in the frontal cortex, but not the hippocampus, of freely-moving rats. The actions of these antagonists were stereospecifically mimicked by (+)S14297 (1.25), whereas its inactive distomer, (-)S17777, was ineffective. The preferential D(2) receptor antagonist, L741,626 (10.0), failed to modify levels of ACh. S33084 (0.01-0.63) and SB277,011 (0.16-2.5) also mimicked tacrine (0.04-0.63) by dose-dependently attenuating the deleterious influence of scopolamine (1.25) upon social memory (recognition by an adult rat of a juvenile conspecific). Further, (+)S14297 (1.25) versus (-)S17777 stereospecifically blocked the action of scopolamine. Using an intersession interval of 120 min (spontaneous loss of recognition), S33084 (0.04-0.63), SB277,011 (0.16-10.0) and (+)S14297 (0.63-10.0) likewise mimicked tacrine (0.16-2.5) in enhancing social memory. In contrast, L741,626 (0.16-10.0) displayed amnesic properties. In conclusion, selective blockade of D(3) receptors facilitates frontocortical cholinergic transmission and improves social memory in rats. These data support the pertinence of D(3) receptors as a target for treatment of disorders in which cognitive function is compromised.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266737     DOI: 10.1111/j.1471-4159.2006.04262.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  38 in total

Review 1.  Modulators in concert for cognition: modulator interactions in the prefrontal cortex.

Authors:  Lisa A Briand; Howard Gritton; William M Howe; Damon A Young; Martin Sarter
Journal:  Prog Neurobiol       Date:  2007-06-30       Impact factor: 11.685

2.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

Review 3.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

4.  Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

Authors:  David J G Watson; Florence Loiseau; Manuela Ingallinesi; Mark J Millan; Charles A Marsden; Kevin C F Fone
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

5.  Dopamine counteracts octopamine signalling in a neural circuit mediating food response in C. elegans.

Authors:  Satoshi Suo; Joseph G Culotti; Hubert H M Van Tol
Journal:  EMBO J       Date:  2009-07-16       Impact factor: 11.598

6.  Hippocampal neurofibromin and amyloid precursor protein expression in dopamine D3 receptor knock-out mice following passive avoidance conditioning.

Authors:  Agata Grazia D'Amico; Alessandro Castorina; Gian Marco Leggio; Filippo Drago; Velia D'Agata
Journal:  Neurochem Res       Date:  2012-12-16       Impact factor: 3.996

7.  Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

Authors:  Manolo Mugnaini; Laura Iavarone; Palmina Cavallini; Cristiana Griffante; Beatrice Oliosi; Chiara Savoia; John Beaver; Eugenii A Rabiner; Fabrizio Micheli; Christian Heidbreder; Anne Andorn; Emilio Merlo Pich; Massimo Bani
Journal:  Neuropsychopharmacology       Date:  2012-09-12       Impact factor: 7.853

8.  Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.

Authors:  Florence Loiseau; Anne Dekeyne; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2007-10-06       Impact factor: 4.530

9.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

10.  Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.

Authors:  Wolfgang Oertel; Werner Poewe; Erik Wolters; Peter Paul De Deyn; Murat Emre; Courtney Kirsch; Chuanchieh Hsu; Sibel Tekin; Roger Lane
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.